Company GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 19:35:29 13/02/2026 +03			5-day change	1st Jan Change
2,165.00 ^GBX	+1.12%		-1.50%	+18.66%

02-13	GSK : Receives a Buy rating from Jefferies	ZD
02-13	Bernstein, Barclays and Deutsche lower Relx	AN

Business description: GSK plc

GSK plc is a global biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Number of employees: 68,629

Sales by Activity: GSK plc

Fiscal Period: December	2020 (GBP)	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)
Commercial Operations	-	-	29.32B	30.33B	31.38B
Corporate and Other Unallocated Turnover	28M	-	-	-	-
Consumer Healthcare	10.03B	9.61B	-	-	-
Vaccines	6.98B	6.78B	-	-	-
Pharmaceuticals	17.06B	17.73B	-	-	-

See all business segments

Geographical breakdown of sales: GSK plc

Fiscal Period: December	2020 (GBP)	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)
United States (US)	14.56B	15.09B	14.54B	15.82B	16.38B
International	18.56B	18.05B	14.09B	13.82B	14.28B
United Kingdom (UK)	980M	975M	695M	693M	708M

See all geographic segments

Executive Committee: GSK plc

Manager	Title	Age	Since
Luke Miels CEO	Chief Executive Officer	-	01/01/2026
Julie Brown DFI	Director of Finance/CFO	64	01/05/2023
Shobie Ramakrishnan CTO	Chief Tech/Sci/R&D Officer	-	01/12/2021
James Ford CMP	Compliance Officer	-	01/08/2018
Tony Wood CTO	Chief Tech/Sci/R&D Officer	-	19/01/2022

See GSK PLC governance

Composition of the Board of Directors: GSK plc

Director	Title	Age	Since
Hal Barron BRD	Director/Board Member	64	01/01/2018
Jonathan Symonds CHM	Chairman	68	01/09/2019
Charles Bancroft BRD	Director/Board Member	66	01/05/2020
Anne Beal BRD	Director/Board Member	63	06/05/2021
Harry Dietz BRD	Director/Board Member	68	01/01/2022
Vishal Sikka BRD	Director/Board Member	59	18/07/2022
Elizabeth Anderson BRD	Director/Board Member	68	01/09/2022
Julie Brown BRD	Director/Board Member	64	01/05/2023
Wendy Becker BRD	Director/Board Member	60	01/10/2023
Jeannie Lee BRD	Director/Board Member	-	04/03/2024

Composition of the Board of Directors

Shareholders: GSK plc

Name	Equities	%	Valuation
The Vanguard Group, Inc. 2.769 %	112,856,911	2.769 %	2 906 M p
Dodge & Cox 2.438 %	99,377,874	2.438 %	2 559 M p
Schroder Investment Management Ltd. 1.65 %	67,238,966	1.65 %	1 731 M p
Norges Bank Investment Management 1.604 %	65,370,000	1.604 %	1 683 M p
BlackRock Advisors (UK) Ltd. 1.575 %	64,194,517	1.575 %	1 653 M p

Name	Equities	%	Valuation
Dodge & Cox 3.362 %	68,517,969	3.362 %	3 536 M p
Fidelity Management & Research Co. LLC 3.246 %	66,143,500	3.246 %	3 413 M p
Fisher Asset Management LLC 1.629 %	33,195,985	1.629 %	1 713 M p
PRIMECAP Management Co. 1.233 %	25,130,160	1.233 %	1 297 M p
JTC Employer Solutions Trustee Ltd. 0.708 %	14,428,009	0.708 %	744 M p

List of GSK PLC shareholders

Holdings: GSK plc

Name	Equities	%	Valuation
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED 75%	127,054,524	75%	3 311 M $
GLAXOSMITHKLINE PAKISTAN LIMITED 82.59%	263,029,794	82.59%	394 M $
HALEON PAKISTAN LIMITED 85.79%	100,423,259	85.79%	337 M $
WAVE LIFE SCIENCES LTD. 9.97%	18,245,691	9.97%	236 M $
CRISPR THERAPEUTICS AG 3.38%	3,220,627	3.38%	161 M $
BIONTECH SE 0.37%	889,824	0.37%	101 M $
VIR BIOTECHNOLOGY, INC. 6.15%	8,550,954	6.15%	64 M $
IDEAYA BIOSCIENCES, INC. 1.52%	1,333,333	1.52%	43 M $
LYELL IMMUNOPHARMA, INC. 7.12%	1,512,659	7.12%	36 M $
DONG-A SOCIO HOLDINGS CO., LTD. 6.46%	421,983	6.46%	32 M $

Company details: GSK plc

GSK Plc

79 New Oxford Street

WC1A 1DG, London

+44 20 8047 5000

http://www.gsk.com

Group companies: GSK plc

Name	Category and Sector
GlaxoSmithKline IHC Ltd. GlaxoSmithKline IHC Ltd. Provides banking services
GlaxoSmithKline Ltd. GlaxoSmithKline Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Ltd. is a company based in Hong Kong, Hong Kong.	Pharmaceuticals: Major
GlaxoSmithKline Ltd. GlaxoSmithKline Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Ltd. is a company based in Hong Kong, Hong Kong.	Pharmaceuticals: Major
Corixa Corp. Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products	Biotechnology
Corixa Corp. Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products	Biotechnology

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GSK PLC	+1.12%	-1.50%	+50.87%	+47.28%	118B
ELI LILLY AND COMPANY	+0.33%	-1.72%	+23.18%	+199.23%	929B
JOHNSON & JOHNSON	-0.45%	+1.44%	+55.91%	+50.24%	587B
ABBVIE INC.	+1.76%	+3.61%	+20.03%	+51.71%	409B
ROCHE HOLDING AG	+0.08%	+1.01%	+22.24%	+29.31%	374B
ASTRAZENECA PLC	+1.42%	+7.19%	+29.13%	+31.26%	320B
NOVARTIS AG	+1.08%	+4.32%	+31.22%	+55.61%	311B
MERCK & CO., INC.	+1.82%	-0.43%	+46.26%	+11.65%	301B
NOVO NORDISK A/S	+1.32%	+5.11%	-44.29%	-37.51%	219B
AMGEN INC.	+1.52%	-3.94%	+26.80%	+53.17%	199B
Average	+1.00%	+1.65%	+26.13%	+49.20%	376.72B
Weighted average by Cap.	+0.76%	+1.48%	+27.99%	+75.77%